Futura Medical

is a research and development pharmaceutical company developing a portfolio of innovative products based on our proprietary, transdermal DermaSys® drug delivery technology.

Our lead product MED2005, is a novel topical treatment for erectile dysfunction currently in Phase 3 clinical trial with potential peak sales of $1bn.

Our purpose is to enhance our patients and consumers’ quality of life through deep science to enable them to live their lives to the full.

Read more

News

  • Phase 3 Results

    Ken James speaks to Proactive London's Andrew Scott following the read-out from the phase III clinical trial of its erectile dysfunction gel.

View more videos


Read more

Share Price

Read more

Results, Reports and Presentations

Annual Report 2018 Thumbnail

Download our latest interim report 2019.

Read more

Our Products

Futura Medical is developing a portfolio of innovative products for two large markets, sexual health and pain. We have a number of products in development, with MED2005 and TPR100 being the lead products.

Read more

MED2005

Lead product MED2005, is the only easy to use topical treatment for erectile dysfunction.

MED2005 is a topical glyceryl trinitrate (GTN) gel which has the potential to be a highly differentiated therapy, especially for mild to moderate ED.

Read more

TPR100

TPR100 is a topical non-steroidal anti-inflammatory for the pain and inflammation associated with sprains, strains and bruises and soft tissue rheumatism.

Read more

DermaSys® Technology

Our unique patented technology DermaSys® provides rapid and targeted local delivery of active pharmaceutical ingredients at therapeutic levels to the required site of action.

Read more

Investor Centre

Our investor centre includes all key investor information such as corporate documents, share price chart and the information required pursuant to AIM Rule 26.

Futura has a proven track record in delivery and completion of Research & Development projects up to value inflection points at which they are suitable for commercialisation partners.

Read more

Our Strategy

Current therapeutic areas are sexual health and pain relief. Development and commercialisation strategies are designed to maximise product differentiation and value creation whilst seeking to minimise risk.

Read more